Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation
Authors' conclusion
GLP-1 RA in KT recipients with T2DM was associated with reduced mortality, and improved kidney function compared to the reference group. Larger, prospective studies are needed to fully evaluate the risks and benefits of GLP-1 RA therapy in KT recipients.
Study context
- Population
- Kidney transplant recipients with T2D; mean (SD) age at transplant 57.9 (9.5) and 60.8 (9.5) years in treatment and reference groups
- Participants
- 77 vs 2,094
- Exposure
- GLP-1 RA vs no GLP-1 RA in kidney transplant (KT) recipients
- GLP-1 RAn = 77
- Referencen = 2,094reference
- Outcome
- Mortality
- Follow-up
- Median 1.5 (IQR 0.99, 2.4) treatment; 5.8 (IQR 3.4, 9.1) years reference
Methodological detailstime-dependent Cox regression, stratified by race-ethnicity
- Time-dependent Cox regression
- Stratified by race-ethnicity
Main finding
As reported in the abstract
- GLP-1 RA vs Reference: P = 0.049
Observational data: associations, not effects.
Further findings
eGFR decline · slower decline with GLP-1 RA
P = 0.04
| Outcome | Net reduction (mg/g per year) | P value |
|---|---|---|
| Urine albumin to creatinine ratioDecreased with GLP-1 RA | 10.62 | P = 0.003 |
Troponin levels
- Lower troponin levels with GLP-1 RA use
Original publication
Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation. Endocr Pract. Published 5 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →